Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNG2 | P59768 | 1/20 | 0.74 |
| ▸ | GNB1 | P62873 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.55 |
| ▸ | SMAD3 | P84022 | 2/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CHAT | P28329 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740272 | 1.00 | GNG2 (0.74) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL3624632 | 0.90 | GNG2 (0.65) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL30451804 | 0.89 | GNG2 (0.63) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL8607854 | 0.88 | FTO (0.73) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL29942282 | 0.85 | GNG2 (1.00) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL334144 | 0.85 | GNG2 (1.00) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL29424349 | 0.85 | GNG2 (1.00) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL30408346 | 0.85 | GNG2 (1.00) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL17201722 | 0.84 | GNG2 (0.76) | GNG2GNB1MAPTMEN1KMT2A | |
| SCHEMBL3654970 | 0.83 | GNG2 (0.74) | GNG2GNB1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230310285-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | L'OREAL (FR) | 2023-10-05 | — | — | US | claimed |
| WO-2023192788-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | L'OREAL (FR) | 2023-10-05 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| EP-1192450-B1 | HIGH ENERGY PHOTOTHERAPEUTIC AGENTS | PROVECTUS PHARMATECH INC (US) | 2014-12-03 | — | — | EP | claimed |
| EP-1753467-B1 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING RADIOLABELED HALOGENATED XANTHENES AND METHODS FOR POSITRON EMISSION IMAGING WITH RADIOLABELED HALOGENATED XANTHENE DIAGNOSTIC AGENTS | PROVECTUS PHARMATECH INC (US) | 2013-01-09 | — | — | EP | claimed |
| US-7427389-B2 | Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes | PROVECTUS PHARMATECH, INC. (US) | 2008-09-23 | — | — | US | claimed |
| EP-1753467-A4 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING RADIOLABELED HALOGENATED XANTHENES AND METHODS FOR POSITRON EMISSION IMAGING WITH RADIOLABELED HALOGENATED XANTHENE DIAGNOSTIC AGENTS | XANTECH PHARMACEUTICALS INC (US) | 2008-09-17 | — | — | EP | claimed |
| EP-1311261-B1 | MEDICAMENTS FOR CHEMOTHERAPEUTIC TREATMENT OF DISEASE | PHOTOGEN INC (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1292298-B1 | INTRACORPOREAL MEDICAMENTS FOR HIGH ENERGY PHOTOTHERAPEUTIC TREATMENT OF DISEASE | PHOTOGEN INC (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1292298-A1 | INTRACORPOREAL MEDICAMENTS FOR HIGH ENERGY PHOTOTHERAPEUTIC TREATMENT OF DISEASE | Photogen, Inc. (US) | 2003-03-19 | — | — | EP | claimed |
| EP-1284727-A1 | INTRACORPOREAL MEDICAMENTS FOR PHOTODYNAMIC TREATMENT OF DISEASE | Photogen, Inc. (US) | 2003-02-26 | — | — | EP | claimed |
| US-20020161035-A1 | Medicaments for chemotherapeutic treatment of disease | PHOTOGEN, INC. | 2002-10-31 | — | — | US | claimed |
| EP-1210078-A1 | IMPROVED TOPICAL MEDICAMENTS AND METHODS FOR PHOTODYNAMIC TREATMENT OF DISEASE | Photogen, Inc. (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2002005812-A1 | MEDICAMENTS FOR CHEMOTHERAPEUTIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| US-20020001567-A1 | Intracorporeal medicaments for high energy phototherapeutic treatment of disease | PHOTOGEN, INC. | 2002-01-03 | — | — | US | claimed |
| WO-2001076595-A1 | INTRACORPOREAL MEDICAMENTS FOR HIGH ENERGY PHOTOTHERAPEUTIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001072301-A1 | INTRACORPOREAL MEDICAMENTS FOR PHOTODYNAMIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| US-20010022970-A1 | Intracorporeal medicaments for photodynamic treatment of disease | PHOTOGEN, INC. | 2001-09-20 | — | — | US | claimed |
| WO-2001012181-A1 | IMPROVED TOPICAL MEDICAMENTS AND METHODS FOR PHOTODYNAMIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310285-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | TYR, CYB5R3, POLR1C | GNG2 1706/4885GNB1 2112/4885MAPT 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.